NCT01277042View on ClinicalTrials.gov

Study to Assess Immune Responses and Safety of the GSK-580299 Vaccine in Healthy Women (26 to 45 Years)

PHASE3CompletedINTERVENTIONAL
Enrollment

1,212

Participants

Timeline

Start Date

February 17, 2011

Primary Completion Date

September 26, 2011

Study Completion Date

February 28, 2012

Conditions
Infections, Papillomavirus
Interventions
BIOLOGICAL

GSK580299 (CervarixTM)

3-dose schedule intramuscularly vaccination (Months 0, 1 and 6)

BIOLOGICAL

Engerix-BTM

3-dose schedule intramuscularly vaccination (Months 0, 1 and 6)

Trial Locations (1)

213200

GSK Investigational Site, Jintan

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01277042 - Study to Assess Immune Responses and Safety of the GSK-580299 Vaccine in Healthy Women (26 to 45 Years) | Biotech Hunter | Biotech Hunter